obesity, Risks and Ozempic and Mounjaro

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions.
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.